Citi analyst Joel Beatty lowered his price target for Amarin to $20 after the company’s 2019 revenue guidance came in lower than he expected. The analyst, however, continues to view Vascepa as an “attractive and differentiated cardiovascular risk reduction therapy.” His peak sales estimate is now $2.5B, down from $3.0B previously.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.